Biobanking 3.0: Evidence based and customer focused biobanking

Clinical Biochemistry

Volumn 47, Issue 4-5, 2014, Pages 300-308

  Simeon Dubach, Daniel ^a   Watson, Peter ^b,c  

^a Medservice Biobanking consulting and services ^*  (Switzerland)

^b BRITISH COLUMBIA CANCER AGENCY   (Canada)

^c UNIVERSITY OF BRITISH COLUMBIA   (Canada)

Author keywords

Biobank; Biobanking 3.0; Customer focus; Infrastructure; Quality; Stakeholders; Sustainability

Indexed keywords

ARTICLE; BIOBANKING 3 0; BLOOD BANK; CANCER RESEARCH; CROSS TRAINING; DONOR; DRUG INDUSTRY; EVIDENCE BASED PRACTICE; HEALTH CARE FACILITY; HEALTH ECONOMICS; HUMAN; MEDICAL INFORMATION SYSTEM; PERSONALIZED MEDICINE; PRIORITY JOURNAL; REPRODUCIBILITY; TRANSLATIONAL RESEARCH;

BIOBANK; BIOBANKING 3.0; CUSTOMER-FOCUS; INFRASTRUCTURE; QUALITY; STAKEHOLDERS; SUSTAINABILITY;

BIOLOGICAL SPECIMEN BANKS; BIOMEDICAL RESEARCH; CAPITAL FINANCING; HUMANS; INFORMATION DISSEMINATION; MARKETING OF HEALTH SERVICES; QUALITY CONTROL; SOCIAL RESPONSIBILITY; SPECIMEN HANDLING;

EID: 84896040934     PISSN: 00099120     EISSN: 18732933     Source Type: Journal    
DOI: 10.1016/j.clinbiochem.2013.12.018     Document Type: Article

References (69)

1. Park A. 10 ideas changing the world right now Mar 23 2009, Time Magazine.
2. Vaught J., Rogers J., Carolin T., Compton C. Biobankonomics: developing a sustainable business model approach for the formation of a human tissue biobank. J Natl Cancer Inst Monogr 2011, 2011(42):24-31.
3. ISBER International Society of Biological and Environmental Repositories. ISBER Available from: URL:. http://www.isber.org.
4. P3G Public Population Project in Genomics and Society. Website Available from: URL:. http://www.p3g.org.
5. ESBB European, Middle Eastern & African Society for Biopreservation & Biobanking. ESBB Available from: URL:. http://www.esbb.org/.
6. BBRB Biorepositories and Biospecimen Research Branch. website 13A.D Available from: URL:, [May 27]. http://biospecimens.cancer.gov/default.asp.
7. CTRNet The Canadian Tumour Repository Network. website Available from: URL:. http://www.ctrnet.ca/.
8. BBMRI Biobanking and Biomolecular Resource Research Infrastructure. BBMRI Available from: URL:. http://www.bbmri.eu.
9. ISBER 2012 best practices for repositories: collection, storage, retrieval, and distribution of biological material for research. Biopreserv Biobank 2012, 10(2):79-161.
10. OECD Creation and governance of human genetic databases 2006.
11. OECD OECD guidelines on human biobanks and genetic research databases 2009.
12. Shickle D., Griffin M., El-Arifi K. Inter- and intra-biobank networks: classification of biobanks. Pathobiology 2010, 77(4):181-190.
13. Asslaber M., Zatloukal K. Biobanks: transnational, European and global networks. Brief Funct Genomic Proteomic 2007, 6(3):193-201.
14. Mabile L., Dalgleish R., Thorisson G.A., Deschenes M., Hewitt R., Carpenter J., et al. Quantifying the use of bioresources for promoting their sharing in scientific research. Gigascience 2013, 2(1):7.
15. Watson P.H., Barnes R.O. A proposed schema for classifying human research biobanks. Biopreserv Biobank 2011, 9(4):327-333.
16. Hewitt R., Watson P.H. Defining biobank. Biopreserv Biobank 2013, 11(5):309-315.
17. The Academy of Medical Science Realizing the potential of stratified medicine Jul 2013, The Academy of Medical Science, UK.
18. Kern S.E. Why your new cancer biomarker may never work: recurrent patterns and remarkable diversity in biomarker failures. Cancer Res 2012, 72(23):6097-6101.
19. Rogers J., Carolin T., Vaught J., Compton C. Biobankonomics: a taxonomy for evaluating the economic benefits of standardized centralized human biobanking for translational research. J Natl Cancer Inst Monogr 2011, 42:32-38.
20. Bjugn R., Hansen J. Learning by erring: fire. Biopres Biobank 2013, 11(4):202-205.
21. Roswall N., Halkjaer J., Overvad K., Tjonneland A. Measures taken to restore the Danish diet, cancer and health biobank after flooding: a framework for future biobank restorations. Biopreserv Biobank 2013, 11(4):206-210.
22. Morrin H.R., Robinson B.A. Sustaining a biobank through a series of earthquake swarms: lessons learned from our New Zealand experience. Biopreserv Biobank 2013, 11(4):211-215.
23. Mintzer J.L., Kronenthal C.J., Kelly V., Seneca M., Butler G., Fecenko-Tacka K., et al. Preparedness for a natural disaster: how Coriell planned for hurricane Sandy. Biopreserv Biobank 2013, 11(4):216-220.
24. Simeon-Dubach D., Zaayenga A., Henderson M.K. Disaster and recovery: the importance of risk assessment and contingency planning of biobanks. Biopreserv Biobank 2013, 11(3):133-134.
25. Wichmann H.E., Kuhn K.A., Waldenberger M., Schmelcher D., Schuffenhauer S., Meitinger T., et al. Comprehensive catalog of European biobanks. Nat Biotechnol 2011, 29(9):795-797.
26. Cole A., Cheah S., Dee S., Hughes S., Watson P.H. Biospecimen use correlates with emerging techniques in cancer research: impact on planning future biobanks. Biopreserv Biobank 2012, 10(6):518-525.
27. Zika E., Paci D., Braun A., Rijkers-Defrasne S., Deschenes M., Fortier I., et al. A European survey on biobanks: trends and issues. Public Health Genomics 2011, 14(2):96-103.
28. Henderson G.E., Cadigan R.J., Edwards T.P., Conlon I., Nelson A.G., Evans J.P., et al. Characterizing biobank organizations in the U.S.: results from a national survey. Genome Med 2013, 5(1):3.
29. Eiseman E., Haga S. A handbook of human tissue sources: a national resource of human tissue samples 2009, RAND Corporation, Santa Monica, CA, USA.
30. Scudellari M. Biobank managers bemoan underuse of collected samples. Nat Med 2013, 19(3):253.
31. Gee S., Georghiou L., Oliver R., Yuille M. Financing UK biobanks: Rationale for a National Biobank Research Infrastructure. WP7: Cost Model, Final Report http://www.stratumbiobanking.org.
32. Massett H.A., Atkinson N.L., Weber D., Myles R., Ryan C., Grady M., et al. Assessing the need for a standardized cancer HUman Biobank (caHUB): findings from a national survey with cancer researchers. J Natl Cancer Inst Monogr 2011, 42:8-15.
33. Ioannidis J.P.A. Why most published research findings are false. PLoS Med 2005, 2(8):e124.
34. Prinz F., Schlange T., Asadullah K. Believe it or not: how much can we rely on published data on potential drug targets?. Nat Rev Drug Discov 2011, 10(9):712.
35. Begley C.G., Ellis L.M. Drug development: raise standards for preclinical cancer research. Nature 2012, 483(7391):531-533.
36. Nieminen P., Carpenter J., Rucker G., Schumacher M. The relationship between quality of research and citation frequency. BMC Med Res Methodol 2006, 6:42.
37. Villanueva J., Shaffer D.R., Philip J., Chaparro C.A., Erdjument-Bromage H., Olshen A.B., et al. Differential exoprotease activities confer tumor-specific serum peptidome patterns. J Clin Invest 2006, 116(1):271-284.
38. McDonald R.J., Cloft H.J., Kallmes D.F. Fate of manuscripts previously rejected by the American Journal of Neuroradiology: a follow-up analysis. AJNR Am J Neuroradiol 2009, 30(2):253-256.
39. Simeon-Dubach D., Perren A. Better provenance for biobank samples. Nature 2011, 475(7357):454-455.
40. Simeon-Dubach D. What do publishers of biomedical journals do to improve the information about pre-analytical variables of biospecimens?. Biopreserv Biobank 2012, 10:183. [HT05].
41. Moore H.M., Kelly A.B., Jewell S.D., McShane L.M., Clark D.P., Greenspan R., et al. Biospecimen reporting for improved study quality (BRISQ). Biopreserv Biobank 2011, 9:57-70.
42. Simeon-Dubach D., Burt A.D., Hall P.A. Quality really matters: the need to improve specimen quality in biomedical research. J Pathol 2012, 228:431-433.
43. Simeon-Dubach D., Burt A.D., Hall P.A. Quality really matters: the need to improve specimen quality in biomedical research. Histopathology 2012, 61(6):1003-1005.
44. Nature editorial Announcement: reducing our irreproducibility. Nature 2013, 496:398.
45. Silberman S. Libraries of flesh: the story state of human tissue storage 2010 May, WIRED Magazine, Available from: URL: www.wired.com/magazine/2010/05/ff_biobanks/aal/1.
46. Osherovich L. Hedging against academic risk. SciBX Apr 14 2011, 4(15).
47. Vaught J., Rogers J., Myers K., Lim M.D., Lockhart N., Moore H., et al. An NCI perspective on creating sustainable biospecimen resources. J Natl Cancer Inst Monogr 2011, 42:1-7.
48. Scott C.T., Caulfield T., Borgelt E., Illes J. Personal medicine-the new banking crisis. Nat Biotechnol 2012, 30(2):141-147.
49. von Walcke-Wulffen V. Fraunhofer IBTM Report: case study on the economic impact of biobanks illustrated by EuroCryo Saar. Fraunhofer Institute for Biomedical Engineering (IBMT) Sep 2009.
50. Foster M.W., Sharp R.R. Will investments in large-scale prospective cohorts and biobanks limit our ability to discover weaker, less common genetic and environmental contributors to complex diseases?. Environ Health Perspect 2005, 113(2):119-122.
51. Watts G., Will U.K. Biobank pay off?. BMJ 2006, 332(7549):1052.
52. Research Markets Global market data for repositories up to 2015 http://www.researchandmarkets.com/reports/1955770/biobanking_technologies_a_global_market_watch.
53. Visiongain Biobanking for medicine: technology and market 2013-2023 http://www.visiongain.com/Press_Release/376/'Biobanking-market-will-reach-24-4bn-in-2017-with-further-growth-to-2023'-predicts-visiongain-in-new-report.
54. Currat-Zweifel C., Leyvraz S., Simeon-Dubach D., Horisberger J.D., Stamenkovic I. Survey of biobanks at a Swiss University Hospital. Biopreserv Biobank 2010, 7:196-197. [HSR17].
55. Gerlinger M., Rowan A.J., Horswell S., Larkin J., Endesfelder D., Gronroos E., et al. Intratumor heterogeneity and branched evolution revealed by multiregion sequencing. N Engl J Med 2012, 366(10):883-892.
56. Basik M., Aguilar-Mahecha A., Rousseau C., Diaz Z., Tejpar S., Spatz A., et al. Biopsies: next-generation biospecimens for tailoring therapy. Nat Rev Clin Oncol 2013, 10(8):437-450.
57. Broom R.J., Tang P.A., Simmons C., Bordeleau L., Mulligan A.M., O'Malley F.P., et al. Changes in estrogen receptor, progesterone receptor and Her-2/neu status with time: discordance rates between primary and metastatic breast cancer. Anticancer Res 2009, 29(5):1557-1562.
58. Thompson A.M., Jordan L.B., Quinlan P., Anderson E., Skene A., Dewar J.A., et al. Prospective comparison of switches in biomarker status between primary and recurrent breast cancer: the Breast Recurrence In Tissues Study (BRITS). Breast Cancer Res 2010, 12(6):R92.
59. Macfarlane R., Seal M., Speers C., Woods R., Masoudi H., Aparicio S., et al. Molecular alterations between the primary breast cancer and the subsequent locoregional/metastatic tumor. Oncologist 2012, 17(2):172-178.
60. van de Ven S., Smit V.T., Dekker T.J., Nortier J.W., Kroep J.R. Discordances in ER, PR and HER2 receptors after neoadjuvant chemotherapy in breast cancer. Cancer Treat Rev 2011, 37(6):422-430.
61. Kinsella M.D., Nassar A., Siddiqui M.T., Cohen C. Estrogen receptor (ER), progesterone receptor (PR), and HER2 expression pre- and post-neoadjuvant chemotherapy in primary breast carcinoma: a single institutional experience. Int J Clin Exp Pathol 2012, 5(6):530-536.
62. Seferina S.C., Nap M., van den Berkmortel F., Wals J., Voogd A.C., Tjan-Heijnen V.C. Reliability of receptor assessment on core needle biopsy in breast cancer patients. Tumour Biol 2013, 34(2):987-994.
63. LeBlanc J., Dee S., Braun L., Daudt H., Cheah S., Watson P.H. Impact of a Permission to Contact (PTC) platform on biobank enrollment and efficiency. Biopreserv Biobank 2013, 11(3):144-148.
64. Matharoo-Ball B., Wooslton C., Elliott J., Locke T., Taylor S., Thomson B. Patient public involvement (PPI) in consenting for biobanks. Biopreserv Biobank 2013, 11(3). [A-4 ELSI 06].
65. Compton C. Getting to personalized cancer medicine: taking out the garbage. Cancer 2007, 110(8):1641-1643.
66. Cambon-Thomsen A., Thorisson G.A., Mabile L. The role of a bioresource research impact factor as an incentive to share human bioresources. Nat Genet Jun 2011, 43(6):503-504.
67. Matzke E.A.M., O'Donoghue S., Barnes R.O., Daudt H., Cheah S., Suggit A., et al. Certification for biobanks: the program developed by the Canadian Tumour Repository Network (CTRNet). Biopreserv Biobank 2012, 10(5):426-432.
68. Hughes S.E., Barnes R.O., Watson P. Biospecimen use in cancer research over two decades. Biopres Biobank 2010, 8(2):89-97.
69. McShane L.M., Altman D.G., Sauerbrei W., Taube S.E., Gion M., Clark G.M. REporting recommendations for tumour MARKer prognostic studies (REMARK). Br J Cancer 2005, 93(4):387-391.